This study is in progress, not accepting new patients
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Summary
- Eligibility
- for people ages 10-65 (full criteria)
- Location
- at UC Irvine UCLA UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Meyeon Park (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Meyeon Park (ucsf)
My research focuses on patient outcomes in genetic kidney diseases including polycystic kidney disease and APOL1-mediated kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated
- ID
- NCT05312879
- Phase
- Phase 2/3 Kidney Disease Research Study
- Study Type
- Interventional
- Participants
- About 522 people participating
- Last Updated